Apollo Health Ventures

Apollo Health Ventures operates as a distinctive transatlantic venture capital organization specializing in early-stage healthcare investments with a specific focus on addressing age-related diseases and the fundamental processes of aging. Founded with the mission to transform healthcare through innovative approaches to longevity science, Apollo has established itself as a pioneering investor in the rapidly expanding longevity sector. The firm employs a unique hybrid model, not only providing capital but actively participating in the co-founding and development of portfolio companies, offering strategic guidance throughout their growth trajectory.

With offices in both Europe and North America, Apollo leverages its transatlantic presence to identify promising scientific breakthroughs and entrepreneurial talent across multiple innovation hubs. The firm's investment strategy typically targets pre-seed to Series A opportunities, with particular emphasis on translational research emerging from prestigious academic institutions. Apollo's portfolio encompasses companies developing novel therapeutics, diagnostics, and platform technologies designed to extend healthy human lifespan by targeting the hallmarks of aging and age-associated diseases.

The Apollo team brings together exceptional expertise in life sciences, venture creation, and company building, with many team members holding advanced degrees in relevant scientific disciplines and extensive experience in biotechnology investment. This deep domain knowledge enables Apollo to evaluate complex scientific concepts and provide meaningful support beyond financial backing. The firm has developed a robust network of scientific advisors, industry partners, and follow-on investors who contribute to the success of portfolio companies through collaborative research, licensing opportunities, and participation in subsequent funding rounds.

Apollo's investment philosophy is grounded in the conviction that targeting the biological mechanisms of aging represents the most promising approach to addressing multiple age-related conditions simultaneously. Rather than focusing solely on symptom management, the firm prioritizes companies developing interventions that address the root causes of aging at the cellular and molecular levels. This approach has positioned Apollo at the forefront of the longevity biotechnology revolution, as the firm continues to build a diverse portfolio of companies working on senolytic therapies, mitochondrial enhancement, epigenetic reprogramming, and other cutting-edge approaches to extending healthy human lifespan.